

Ahmedabad
31.10.2006

PRESS RELEASE

-
- 1. Q2 Net profit up 28%, Sales up 38%**
 - 2. Manufacturing tie-up negotiations on with international companies**
-

Hester's Net Profit for Q2 ended 30.9.2006 is recorded at Rs. 1.37 crores, as compared to Rs. 1.07 crores for the previous corresponding period, thereby registering an increase in NP by 28%.

Hester has reported a turnover of Rs. 5.57 crores in Q2 ended 30.9.2006 as compared to Rs. 4.04 crores for the previous corresponding period, thereby registering an increase in Sales by 38%.

The company has successfully completed its rights issue and allotted 14,83,200 shares on 19.8.2006, at a price of Rs. 70 per share. The enhanced equity capital now stands at Rs. 5.19 crores as against Rs. 3.71 crores as on 30.6.2006.

EPS has been registered at Rs. 3.11 for Q2 ended 30.9.2006 (on the effective paid up capital - post preferential and rights allotment) as against Rs. 3.05 for the Q2 ended 30.9.2005.

The expansion plan is now scheduled to commence production in January 2007.

Negotiations are on with international companies for manufacturing animal vaccines for their international markets. Such tie-ups will give immediate utilizations of the expanded capacity which is being increased from 120 crore doses to 480 crore doses per annum.

Rajiv Gandhi
CEO & Managing Director
Hester Pharmaceuticals Limited
www.hesterpharma.co.in
rajiv@hesterpharma.co.in